Yong Zhang

Yong Zhang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2023 in Infectious Diseases of Poverty
Verified
Journal Article
Open access
PDF file
XZXue-Lian Zhao
Xue-Lian Zhao
SHShang-Ying Hu
Shang-Ying Hu
JHJia-Wei Hu
Jia-Wei Hu
HWHong-Hao Wang
Hong-Hao Wang
TWTian-Meng Wen
Tian-Meng Wen
YZYong Zhang
Yong Zhang
The human papillomavirus (HPV) vaccine is the first vaccine developed specifically targeting the prevention of cervical cancer. For more than 15 years, China has expedited a series of efforts on research and development of the domestically manufactured HPV vaccines, producing local population-based evidence, promoting free HPV vaccination from pilots, and launching action plans to tackle barriers in the scale-up of HPV vaccination. To further roll out the HPV vaccination program in China, several challenges should be addressed to support the steps forward. The availability of more locally manufactured HPV vaccines, pricing negotiation and local evidence supporting the efficacy of one-dose schedule would greatly alleviate the continued supply and financial constraints in China. Meanwhile, more attention should be paid to girls living in low-resource areas and males to ensure equal access to the HPV vaccination. Furthermore, linkage to secondary prevention and further real-world monitoring and evaluation are warranted to inform effective cervical cancer prevention strategies in the post-vaccine era. Graphical Abstract

18 May 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
DSDanhong Song
Danhong Song
PLPeiyi Liu
Peiyi Liu
DWDadong Wu
Dadong Wu
FZFanghui Zhao
Fanghui Zhao
YWYueyun Wang
Yueyun Wang
YZYong Zhang
Yong Zhang
No research has been conducted to explore the variables associated with healthcare providers’ (HCPs) knowledge and attitudes toward the human papillomavirus vaccine (HPV) since the vaccine was approved for free use in some Chinese cities. In Shenzhen, southern China, a convenience sample strategy was used to distribute questionnaires to HCPs involved in the government’s HPV vaccination program from Shenzhen. There were 828 questionnaires collected in total, with 770 used in the analysis. The mean HPV and HPV vaccine knowledge score was 12.0 among HCPs involved in the government HPV vaccination program (with a total score of 15). the average scores for HPV and HPV vaccine knowledge varied among different types of medical institutions. District hospitals had the highest mean score of 12.4, while private hospitals ranked fourth with a mean score of 10.9. Multivariate logistic regression results revealed significant disparities in the type of license and after-tax annual income across HCPs (p < 0.05). The future education and training for HCPs should focus on private community health centers (CHCs), HCPs whose license type is other than a doctor, and HCPs with low after-tax annual income.

3 October 2024 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
TYTingting You
Tingting You
XZXuelian Zhao
Xuelian Zhao
CPChenghao Pan
Chenghao Pan
MGMeng Gao
Meng Gao
SHShangying Hu
Shangying Hu
MJMark Jit
Mark Jit
The high price of HPV vaccines remains a significant barrier to vaccine accessibility in China, hindering the country’s efforts toward cervical cancer elimination and exacerbating health inequity. We aimed to inform HPV vaccine price negotiations by identifying threshold prices that ensure that a government-funded HPV vaccination programme is cost-effective or cost-saving. We used a previously validated transmission model to estimate the health and economic impact of HPV vaccination over a 100-year time horizon from a healthcare payer perspective. Threshold analysis was conducted considering different settings (national, rural, and urban), cervical cancer screening scenarios (cytology-based or HPV DNA-based, with different paces of scale-up), vaccine types (four types available in China), vaccine schedules (two-dose or one-dose), mode of vaccination (routine vaccination with or without later switching to high-valency vaccines), willingness-to-pay thresholds, and decision-making criteria (cost-effective or cost-saving). Furthermore, we examined the budget impact of introducing nationwide vaccination at the identified threshold prices. Using the current market price, national routine HPV vaccination with any currently available vaccine is unlikely cost-effective. Under a two-dose schedule, the prices of the four available HPV vaccine types cannot exceed $26–$36 per dose (44.1%–80.2% reduction from current market prices) depending on vaccine type to ensure the cost-effectiveness of the national programme. Adopting vaccination at threshold prices would require an annual increase of 72.18%–96.95% of the total annual National Immunization Programme (NIP) budget in China. A cost-saving routine vaccination programme requires vaccine prices of $5–$10 per dose (depending on vaccine type), producing a 21.38%–34.23% increase in the annual NIP budget. Adding the second dose is unlikely to be cost-effective compared to a one-dose schedule, with the threshold price approaching or even falling below zero. Rural pilot vaccination programmes require lower threshold prices compared with a national programme. Our study could inform vaccine price negotiation and thus facilitate nationwide scale-up of current HPV vaccination pilot programmes in China. The evidence may potentially be valuable to other countries facing HPV introduction barriers due to high costs. This approach may also be adapted for other contexts that involve the introduction of a pricy vaccine. CAMS Innovation Fund for Medical Sciences (CIFMS); 10.13039/100000865 Bill & Melinda Gates Foundation .

4 December 2024 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
JHJiawei Hu
Jiawei Hu
RDRufei Duan
Rufei Duan
HZHongyun Zhang
Hongyun Zhang
XZXuelian Zhao
Xuelian Zhao
AWAihui Wu
Aihui Wu
YZYong Zhang
Yong Zhang
Cervical cancer is a major health threat in the female population. Human immunodeficiency virus (HIV)-positive women encounter a higher risk of cervical cancer. It is significant to promote cervical cancer screening attendance among HIV-positive women. Little is known about the awareness, attendance, and attitudes toward cervical cancer screening, as well as the associated factors, among Chinese HIV-positive women. A cross-sectional study was conducted among 411 HIV-positive women attending a large ART clinic in Yunnan, an HIV-endemic province in China. Participants were recruited using the convenient sampling method from January 2019 to August 2020. An interviewer-administered semi-structured questionnaire was utilized to collect information on socio-demographic and behavioral characteristics, clinical characteristics related to HIV infection, awareness, attendance, and attitudes toward cervical cancer screening. Binary logistic regression analyses were used to determine factors associated with awareness, attendance, and attitude toward cervical cancer screening. Some 69.8% (287) of the participants were aware of cervical cancer screening, but only 27.7% (114) had attended screening within 3 years. After receiving a brief health education, 72.3% (297) of the participants exhibited a positive attitude toward cervical cancer screening. Participants with a higher education background and longer duration of antiretroviral therapy were more likely to be aware of cervical cancer screening and have up-to-date screening. The up-to-date screening attendance was also influenced by age, smoking status, and health insurance. Single participants were less likely to show a positive attitude toward cervical cancer screening compared married or cohabiting counterparts. The main facilitators to attending cervical cancer screening were health promotion activity and well-organized programs, while the main barriers were high costs of the service and inadequate awareness. Although most HIV-positive women attending a large ART clinic in Yunnan were aware of cervical cancer screening, the up-to-date attendance was low. It is crucial to conduct health education and promotion through efficient channels to improve awareness and attendance. The discrepancy between awareness and attendance also emphasized the importance of adopting appropriate screening strategies and powerful health policies that can foster the attendance of cervical cancer screening among HIV-positive women. Efforts should be devoted to constructing a comprehensive healthcare system with high accessibility in China for cervical cancer prevention and management for HIV-positive women.

13 May 2025 in BMC Public Health
Verified
Journal Article
Open access
PDF file
LYLu Yue
Lu Yue
WRWenhui Ren
Wenhui Ren
LZLe Zhang
Le Zhang
FWFeihong Wu
Feihong Wu
JCJinping Chen
Jinping Chen
YZYong Zhang
Yong Zhang
Timely diagnostic follow-up subsequent to abnormal results is crucial for the efficacy of breast cancer screening programs. We aimed to identify the frequency and women-level factors of loss or delay in the follow-up for screening abnormalities in China. This mixed-methods cohort study comprised a retrospective analysis of ultrasound based breast screening data collected from Boluo (site A), Lilin (site B), and Ordos (site C) in China from 2018 to 2021, and qualitative, semistructured interviews conducted with program leaders from the three local Maternal and Child Health (MCH) hospitals, respectively. According to the screening protocol, we assessed the follow-up of two screening results: (1) mammography after suspicious results in the ultrasound and (2) biopsy after positive results in the ultrasound or supplement mammography. The rates and timeliness of follow-up with diagnostic examinations were compared across the different sites and procedures, and logistic regression was employed to explore the women-level factors influencing failure or delay in follow-up. Of 7,939 women with abnormal screening results, 5,943 (74.86%) received final diagnostic tests, while 4,631 (58.33%) got final diagnosis timely. The follow-up rate for mammography was higher than that for biopsy. Site A performed better in follow-up, with an overall follow-up rate of 98.01%, which may be related to the provision of free biopsy services and the establishment of a robust referral system. Women aged 45 to 54 years (ref: 35–44 years; aOR = 1.18; 95% CI: 1.01, 1.38; P = 0.032) were more likely to be lost to follow-up. Women who had never attended breast screening (ref: ever screened; aOR = 1.15; 95% CI: 1.00, 1.32; P = 0.046) were at high risk for delayed follow-up. Conversely, women with a high level of education (aOR = 0.66; 95% CI: 0.59, 0.73; P < 0.001) and those with abnormal clinical breast examination results (ref: with normal results; aOR = 0.79; 95% CI: 0.69, 0.92; P = 0.002) were more likely to get timely follow-up. The overall follow-up rate and quality among women with abnormal screening results showed significant regional variability, and still required to be improved. Moreover, women with higher age and lower educational levels were particularly at high risk for delayed follow-up care and deserved more attention.

18 August 2025 in Preventive Medicine Reports
Verified
Journal Article
Open access
JHJiawei Hu
Jiawei Hu
HWHonghao Wang
Honghao Wang
SZShuang Zhao
Shuang Zhao
LHLiuye Huang
Liuye Huang
XCXiaoqing Chen
Xiaoqing Chen
FZFanghui Zhao
Fanghui Zhao
This study aimed to investigate cervical cancer screening participation, knowledge of cervical cancer and screening, attitudes toward relevant healthcare services, and associated factors among migrant Burmese women in Mangshi, a county on the China-Myanmar border in Southwest China's Yunnan province. A cross-sectional study was conducted in Mangshi Maternal and Child Health Hospital from October 2020 to December 2021. Migrant Burmese women attending routine gynecological examinations were recruited via convenient sampling. An interviewer-administered questionnaire was utilized to collect data. Logistic regressions were utilized to assess factors associated with cervical cancer screening participation and knowledge level. Among 1504 participants, 31.3 % ever attended cervical cancer screening. In the recommended age group of 25–64 years, the participation rate was 35.2 %. Screening participation was associated with age, marital status, occupation, and history of genital tract infection. Approximately 20.9 % had heard of human papillomavirus, 23.2 % knew cervical cancer is preventable, and 41.6 % had heard of cervical cancer screening. Awareness of risk factors, screening techniques, and symptoms was limited. The median knowledge score was 2.0 out of 19.0. Knowledge level was associated with education, age at menarche, number of sexual partners, and history of genital tract infection. Most (99.7 %) participants were willing to attend cervical cancer screening, but only 84.5 % would accept therapy if necessary. The most common barrier to therapy was unaffordable cost. Migrant Burmese women in Mangshi had suboptimal screening participation and inadequate cervical cancer knowledge. Screening policies should prioritize socioeconomically disadvantaged women. Enhancing targeted health education is essential.